Medullary Thyroid Cancer - Pipeline Review, H2 2016

Date: August 17, 2016
Pages: 100
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MF65BCDAED1EN
Leaflet:

Download PDF Leaflet

Medullary Thyroid Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Medullary Thyroid Cancer - Pipeline Review, H2 2016’, provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
  • The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Medullary Thyroid Cancer Overview
Therapeutics Development
Pipeline Products for Medullary Thyroid Cancer - Overview
Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis
Medullary Thyroid Cancer - Therapeutics under Development by Companies
Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
Medullary Thyroid Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Medullary Thyroid Cancer - Products under Development by Companies
Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes
Medullary Thyroid Cancer - Companies Involved in Therapeutics Development
AbbVie Inc
Advenchen Laboratories, LLC
Bayer AG
Boehringer Ingelheim GmbH
Celgene Corporation
Hutchison MediPharma Limited
Immunomedics, Inc.
Nerviano Medical Sciences S.r.l.
Novartis AG
Pfizer Inc.
Medullary Thyroid Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AL-3818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLM-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLM-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLM-94 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-6207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMS-616 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regorafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rovalpituzumab tesirine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Medullary Thyroid Cancer - Dormant Projects
Medullary Thyroid Cancer - Discontinued Products
Medullary Thyroid Cancer - Product Development Milestones
Featured News & Press Releases
Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Medullary Thyroid Cancer, H2 2016
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Medullary Thyroid Cancer - Pipeline by AbbVie Inc, H2 2016
Medullary Thyroid Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
Medullary Thyroid Cancer - Pipeline by Bayer AG, H2 2016
Medullary Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Medullary Thyroid Cancer - Pipeline by Celgene Corporation, H2 2016
Medullary Thyroid Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
Medullary Thyroid Cancer - Pipeline by Immunomedics, Inc., H2 2016
Medullary Thyroid Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
Medullary Thyroid Cancer - Pipeline by Novartis AG, H2 2016
Medullary Thyroid Cancer - Pipeline by Pfizer Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Medullary Thyroid Cancer - Dormant Projects, H2 2016
Medullary Thyroid Cancer - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Medullary Thyroid Cancer, H2 2016
Number of Products under Development for Medullary Thyroid Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Thyroid Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Jun, 2014 · 121 pages
Follicular Thyroid Cancer - Pipeline Review, H2 2015 US$ 1,600.00 Jul, 2015 · 91 pages
Papillary Thyroid Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 72 pages
Follicular Thyroid Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 83 pages
Papillary Thyroid Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 106 pages

Ask Your Question

Medullary Thyroid Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: